Menu
Search Close

Using immunology to fight cancer

Read more

In Phase 1/2 clinical trials for the treatment of patients with metastatic melanoma

Read more

Novel vaccine platform that destroys tumours 

Read more

Cancer Immunotherapy

Cancer remains one of the world’s most significant diseases. A key challenge in the fight against cancer is that many tumours continue to grow by successfully evading the body’s own natural defence mechanism - the immune system. Scancell’s mission is to overcome this breach in our defences by developing products that stimulate the immune system to treat or prevent cancer.

The company, which was founded in 1997 as a spin-out from the University of Nottingham, has secured £23 million funding to date. In December 2006 Scancell sold its pipeline of direct killing monoclonal antibodies to Arana Therapeutics, an Australian biopharmaceutical company. The deal allowed Scancell to focus its efforts entirely on its innovative ImmunoBody® and Moditope® cancer vaccine programmes.

Read more

Presentation

Scancell Investor Presentation, February 16 2018

 

If you wish to see the full unedited version of this presentation please click here

Aim logo

Scancell Holdings PLC is an AIM listed company

Webcasts, Interviews and Media Coverage

Scancell Holdings part of the new cancer revolution

The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology

Tue, 25 Sep 2018 06:20:00

Scancell Holdings extends collaboration with Sweden's Karolinska Institute

The company first teamed up with Sweden's world-leading medical research university two years ago

Thu, 09 Aug 2018 08:15:00

Scancell Holdings inks drug delivery technology deal

It has exercised an option on TriGrid, which was developed by Ichor Medical Systems

Wed, 18 Jul 2018 06:09:00